Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MyoNanoCell

Financiado

MyoNanoCell: CardioMYOgenic NANOsized CELL-based Vehicles for Cardiac Microenvir...

MyoNanoCell: CardioMYOgenic NANOsized CELL-based Vehicles for Cardiac Microenvironment Modulation and Heart Fibrosis Therapy Cardiovascular diseases are the leading cause of death worldwide, accounting roughly for 45% of all deaths in Europe and costing billions of euros to the European Union economy. Among these, most cardiovascular diseases, such as m... ver más

31/08/2027

UNIVERSITAIR MEDIS...

188K€

Presupuesto del proyecto: 188K€

Líder del proyecto

ACADEMISCH ZIEKENHUIS GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-08

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

UNIVERSITAIR MEDISCH CENTRUM...

187.62K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2019-107150RB-I00 INCAPACITACION DE LAS CELULAS ENDOGENAS DEL TEJIDO CARDIACO... 121K€ Cerrado

SAF2015-69706-R DISEÑO DE ESTRATEGIAS PARA CONTROLAR LA PROLIFERACION, DIFER... 278K€ Cerrado

RTC-2016-4911-1 Desarrollo clínico de una terapia celular para reparación ca... 641K€ Cerrado

RTC-2015-4398-1 Terapia celular basada en progenitores cardiacos para tratam... 2K€ Cerrado

RYC2019-027635-I Myocardial Remodeling and Heart Failure: Novel treatments an... 309K€ Cerrado

MAT2015-62725-ERC BIOMATERIALES INSTRUCTIVOS PARA REGENERACION CARDIACA IN VIV... 62K€ Cerrado

Duración del proyecto: 39 meses Fecha Inicio: 2024-05-08
Fecha Fin: 2027-08-31

Líder del proyecto

ACADEMISCH ZIEKENHUIS GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 188K€

Descripción del proyecto Cardiovascular diseases are the leading cause of death worldwide, accounting roughly for 45% of all deaths in Europe and costing billions of euros to the European Union economy. Among these, most cardiovascular diseases, such as myocardial infarction, lead to the formation of heart scarring, which is the formation of fibrotic tissue that impairs contractility and cardiac function, ultimately causing heart failure. Despite the prevalence and serious consequences of heart fibrosis, current benchmark therapies have low long-term efficacy, and alternative novel therapies that have reached clinical testing still present severe limitations or lead to little improvement in cardiac function. Thus, there is still an urgent unmet need for the development of novel and efficient therapies for cardiac fibrosis. Cutting-edge research regarding the use of stem cells or delivery of molecules to induce cardiomyocyte proliferation are yet to be successful, as most of these therapies present challenges regarding immunogenicity, efficiency, and long-lasting effect. Thereby, MyoNanoCell project aims at developing a radically new platform for heart fibrosis and cardiac regeneration. By using a combinatory approach, where the MyoNanoCell nanohybrids incorporate not only the ability to carry different cardiomyogenic molecules, but also the ability to modulate the cardiac microenvironment and recognize cardiac fibroblasts, MyoNanoCell will radically increase therapeutic efficiency. Moreover, the simultaneous modulation of cardiac microenvironment and its repopulation with cardiomyocytes by fibroblast reprogramming will directly impact contractility and heart function, representing a paradigm shift in cardiac fibrosis therapy. MyoNanoCell will be fully characterized in vitro to have a full biological fingerprint on the process of cell identity shift, and also tested in advanced 3D in vitro models, to evaluate its overall effects at tissue level.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores